Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
BNT162 Vaccine
/ administration & dosage
COVID-19
/ prevention & control
COVID-19 Vaccines
/ administration & dosage
Humans
Immunization Schedule
Immunization, Secondary
Middle Aged
Mutation
Neutralization Tests
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ genetics
T-Lymphocytes
/ immunology
Vaccination
Young Adult
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
11 02 2022
11 02 2022
Historique:
pubmed:
19
1
2022
medline:
19
2
2022
entrez:
18
1
2022
Statut:
ppublish
Résumé
The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)-based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.
Identifiants
pubmed: 35040667
doi: 10.1126/science.abn7591
pmc: PMC9836206
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
678-680Références
N Engl J Med. 2021 Oct 21;385(17):1627-1629
pubmed: 34525276
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
PLoS One. 2011;6(10):e25858
pubmed: 21998709
JAMA. 2022 Jan 18;327(3):279-281
pubmed: 34860253
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
iScience. 2021 Dec 17;24(12):103467
pubmed: 34805783
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Cell Mol Immunol. 2021 Oct;18(10):2307-2312
pubmed: 34471260
China CDC Wkly. 2021 Dec 3;3(49):1049-1051
pubmed: 34934514
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Nature. 2021 Aug;596(7871):273-275
pubmed: 34111888
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
J Clin Epidemiol. 2022 Feb;142:38-44
pubmed: 34715314
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
iScience. 2021 Nov 19;24(11):103393
pubmed: 34746689
Nature. 2021 Apr;592(7853):283-289
pubmed: 33524990
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923